Biomarkers of immunotherapy response in neuro-oncology.

32 , 33 A strong trend toward increased OS was also noted in melanoma BMs with high expression of PD-L1. 34 However, this correlation between PD-L1 expression and treatment response was not seen in a phase 2 trial of atezolizumab (a PD-L1 inhibitor) with carboplatin and pemetrexed in a cohort of patients with nonsquamous NSCLC with untreated BM, 35 suggesting it may not be universally applicable.

also in 5,725 other papers

A nonsignificant trend was also noted between ADC values on MRI and outcome, with higher median ADC values among patients with PFS-6.

also in 5,406 other papers